María Jesús Vivancos is an expert in Infectiology at Hospital Universitario Ramón y Cajal (Spain). María Jesús Vivancos has authored 107 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 1 of them ongoing. SLR score: 379 (community average: 125). How the SLR is computed.

LeadR Profile

María Jesús Vivancos Hospital Universitario Ramón y Cajal Spain
379 ScienceLeadR Reputation 379
Network Map

Infectiology

Subspecialties: Public Health - Pharmacy - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2016 - 2026

Source: PubMed

Hospital Universitario Ramón y Cajal

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 107

Citations

Citations: 1 248 1st author: 10 Last author: 3 Unique author: 1


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Immune Trajectories After Switch to Long-Acting Cabotegravir Plus Rilpivirine in the RELATIVITY Cohort.
PMID 42921238 — cells, rilpivirine, cell count
Open Forum Infect Dis20260
Adherence to European AIDS clinical society hepatitis B management guidelines in people with HIV: real-world evidence from Spain and Germany.
PMID 42847908 — cd4 lymphocyte count, cells, research design, guideline adherence, cross-sectional studies, liver, acquired immunodeficiency syndrome, enzymes, viruses, therapeutics, hepatitis b, infections, hepatitis
AIDS20260
Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV.
PMID 42682263 — sexually transmitted diseases, hepatitis c, incidence, phenotype, acquired immunodeficiency syndrome, hiv, viruses, infections, hepatitis, virus diseases
AIDS20260
Younger age as a key predictor of follow-up abandonment among PrEP users: A retrospective cohort study in Madrid.
PMID 42502983 — sexually transmitted diseases, age factors, pre-exposure prophylaxis, patient dropouts, cohort studies, retention in care, demography, infections
HIV Med20260
Effect of Non-nucleoside Resistance-Associated Mutations on the Effectiveness of Long-Acting Cabotegravir + Rilpivirine Therapy: Insights From the Real-World RELATIVITY Cohort.
PMID 42460401 — nucleosides, rilpivirine, therapeutics, mutation
Open Forum Infect Dis20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 4
Phase 4 2
Phase 1/Phase 2 1

By status:

Completed 5
Recruiting 1
Unknown 1

By type:

Interventional 5
Observational 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 0
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 8

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Tools to Identify People At Risk or Already Infected with HIV and HCV
NCT06528626 — sexually transmitted diseases, laboratories, computers, electronic health records, acquired immunodeficiency syndrome, hiv, health personnel, records, serologic tests, hiv infections, infections, medical records, electronic medical record
N/ARecruiting2023

LeadR Networks

Main global connection map